



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/588,360

10/10/2006

Jean-Marie Gouot

P/4976-37

7220

2352 7590 05/10/2011
OSTROLENK FABER GERB & SOFFEN
1180 AVENUE OF THE AMERICAS
NEW YORK, NY 100368403

EXAMINER

PAK, JOHN D

ART UNIT

PAPER NUMBER

1616

MAIL DATE

DELIVERY MODE

05/10/2011

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/588,360

Applicant(s)

GOUOT ET AL.

Examiner

JOHN PAK

Art Unit

1616

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 10 January 2011.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-20 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-20 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____

- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

Claims 1-20 are pending in this application.

Applicant's election with traverse of Example I, a mixture of Compound of formula I and cyprodinil, in the reply filed on 1/22/2010 is noted again. Applicant is invited to amend the claims to the elected subject matter of record.

Claims 1-20 will presently be examined to the extent that they read on the elected subject matter of record.

Applicant's disqualification of WO 2004/016088 under 35 USC 103(c) was deemed proper in the Office action of 11/2/2010.


The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combined teachings of WO 01/11965 and Hubele (US 5,153,200) in view of HCAPLUS abstract 1995:694232 and Hopkinson (US 6,746,988).

WO 01/11965 broadly discloses applicant's compounds of formula (I) as fungicides. See Example 5 in paragraph 0096 in view of paragraphs 0002 to 0031. The structure of Example 5 compound is drawn below by the undersigned Examiner.

Art Unit: 1616



It is noted that this compound is readable on applicant's independent claim 1, formula (I), and all other dependent claims except dependent claims 8 and 9. Alternative substitution on the phenyl ring moiety is disclosed as including halogen and haloalkyl (C₁₋₆). See paragraphs 26 and 28. Fungicidal activity against fungal diseases of plants such as mildews, cereal powdery mildew, *Erysiphe graminis* and many others are disclosed (paragraph 0037). Combination with other fungicides, insecticides and pesticides is disclosed (paragraph 0041). Concentration of 0.0001 to 1 wt% for direct application and 5 to 95 wt% concentrate strength composition are disclosed (paragraph 0052). 5-1000 g per hectare application rate is disclosed (paragraph 0053). Combination with diluent, carrier, and various additives such as surface active agent dispersing agent, emulsifying agent is disclosed (paragraphs 0042-0051). See treatment is disclosed (paragraph 0053). Soil application and foliar application are disclosed (paragraphs 0053-0054).

Hubele discloses cyprodinil as a well-tolerated fungicide to curatively or preventively protect crops of useful plants (paragraph bridging columns 1-2; column 3, last two lines; column 12, lines 26-39; column 16, Example 1.1). See columns 12-15 for specific disclosures on activity, application, formulation and crops to be protected: 50g

to 5 kg/hectare application rate; 0.1-95 wt% concentration range; formulations with various carriers and surfactants; seed treatment. Activity against various fungal pathogens is disclosed (columns 90-92). Insecticidal activity as well as fungicidal activity is disclosed (column 12, lines 26-30, 53-55). Combinations with other active agents such as other fungicides are disclosed (column 13, first full paragraph).

HCAPLUS abstract 1995:694232 discloses CGA 219417, an earlier name for cyprodinil, as a broad-spectrum fungicide for protection of various crops against many different fungi. Inhibition of methionine mode of action is disclosed, as well as its safety. Flexible use in integrated disease control practices is disclosed.

The patent by Hopkinson et al. is cited to establish that applicant's compound (b) and (c) fungicides are well-known fungicides, which are known to be used in combination. See claim 16, which discloses for example cyprodinil, trifloxystrobin, propineb, tolyfluanid, iprodione and many other well-known fungicides, and mixtures thereof.

The difference between the claimed invention and the cited references is that the references do not expressly disclose the specific combination of compound I + cyprodinil. However, both compounds have been taught by the prior art as agriculturally useful fungicides, and combination with other fungicides has been specifically suggested. Therefore, one having ordinary skill in the art would have been motivated to combine the fungicidal compound of formula I such as compound I with a well-known fungicide such as cyprodinil with the expectation of obtaining an advantageous

Art Unit: 1616

fungicidal mixture, as claimed. In re Kerkhoven, 205 USPQ 1069, 1072 (CCPA 1980); In re Crockett, 126 USPQ 186 (CCPA); Ex parte The NutraSweet Co., 19 USPQ2d 1586, 1587 (Bd. Pat. App. & Int. 1991). Further addition of a third known fungicide such as propineb would have been similarly suggested from the motivation to obtain additional activity and spectrum of control.

Regarding the claimed ratio of 0.01 to 20 (a to b), such ratio would have been obvious from the prior art concentration and application amounts, which when combined at their known amounts and rates would provide such ratio of components.

Applicant's specification data has been reviewed, but the data there is not commensurate in scope with that of the claims. Evidence of nonobviousness, if any, must be commensurate in scope with that of the claimed subject matter. In re Kulling, 14 USPQ2d 1056, 1058 (Fed. Cir. 1990); In re Lindner, 173 USPQ 356, 358 (CCPA 1972).

Specific notes pertaining to applicant's data

(1) Data for Example 1, N-{2-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]ethyl}-2-trifluoromethylbenzamide + cyprodinil is noted, but there is no other evidence that similar result would be obtained with other compounds of formula (I) + cyprodinil. Further explanation or evidence is required.

(2) Applicant has not advanced nonobvious evidence that applicant's compound of formula (I) would combine with cyprodinil, pyrimethanil or any other methionine biosynthesis inhibitor to provide unexpectedly greater efficacy than compound of

Example 5 and other structurally similar compounds disclosed by WO 01/11965 (which are readable on applicant's formula (I) compounds).

For these reasons, applicant's data is found insufficient and not commensurate in scope with that of the claimed subject matter. Therefore, the claimed invention, as a whole, would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made, because every element of the invention and the claimed invention as a whole have been fairly disclosed or suggested by the teachings of the cited references.

Applicant's arguments relative hereto have been given due consideration but they were deemed unpersuasive.

Applicant cites other instances of the Colby method being used to calculate synergism, but applicant fails to cite a higher authority, a decision by the Board of Patent Appeals and Interferences. In Ex parte Quadranti, 25 USQ2d 1071 (Bd. Pat. App. & Intf. 1992), the Board expressly rejected the Colby method as "not particularly useful," which "results in an expectation of a less than additive effect" Id. at 1072.

As explained above, applicant's claims are far broader than the specification data. Hence, even if applicant's data were sufficient evidence of *unexpected* result, it still falls short of being commensurate in scope with that of the claimed subject matter. Applicant has failed to limit the claims to the scope of the specification evidence or provide sufficient reasons why the data shown is probative of unexpected result for the entire claimed subject matter *under examination*.

For these reasons, this ground of rejection must be maintained.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-20 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-12 of U.S. Patent No. 7,776,892.

Although the conflicting claims are not identical, they are not patentably distinct from each other because of the reasons of record.

Applicant's terminal disclaimer of 1/10/2011 is noted. The USPTO division that reviews terminal disclaimers has notified the undersigned examiner that said terminal disclaimer cannot be accepted. The stated reason for non-acceptance is copied below:

☒ Other The language 35 USC 154-156 is unacceptable because 155 and 156 do not define the term of the patent, it should read 35 USC 154 and 173. Refer to the form at the end of Chapter 1400, or the form paragraphs in 1490 or language that is clear and complies with the TD rule.

There appears to be a requirement for strict adherence to the language of patent term. Apparently, including additional sections of the USC is not acceptable. The discrepancy in applicant's terminal disclaimer of 1/10/2011 is pointed out below –

~~application, which would extend beyond the expiration date of the full statutory term, defined in~~
35 U.S.C. §§ 154, 156, and 173 as shortened by any terminal disclaimer filed prior to the grant,
of said U.S. Patent No. 7,776,892. The owner agrees that any patent so granted on the instant
application shall be enforceable only for and during such period that it and said U.S. Patent
No. 7,776,892 are commonly owned. This agreement runs with any patent granted on the instant
application and is binding upon the grantee, its successors, or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any
~~patent granted on the instant application that would extend to the expiration date of the full~~
statutory term, as defined in 35 U.S.C. §§ 145 to 156 and 173, of said U.S. Patent No. 7,776,892,
as shortened by any terminal disclaimer filed prior to its patent grant, in the event that such

Appropriate correction is deemed necessary.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP

§ 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to John Pak whose telephone number is **(571)272-0620**. The Examiner can normally be reached on Monday to Friday from 8 AM to 4:30 PM. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's SPE, Johann Richter, can be reached on **(571)272-0646**.

The fax phone number for the organization where this application or proceeding is assigned is **(571)273-8300**.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571)272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should

Application/Control Number: 10/588,360
Art Unit: 1616

Page 10

you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/John Pak/
Primary Examiner, Art Unit 1616